{"id":"W1979078348","doi":"10.1111/dom.12393","title":"Randomized efficacy and safety trial of once‐daily remogliflozin etabonate for the treatment of type 2 diabetes","year":2014,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline","keywords":"Tolerability; Type 2 diabetes; Placebo; Medicine; Randomized controlled trial; Pioglitazone; Clinical endpoint; Internal medicine; Diabetes mellitus; Pharmacokinetics; Pharmacology; Adverse effect; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003104469,0.001967314,0.005010515,0.0006259857,0.0004788732,0.001078183,0.001201567,0.002219594,0.006033322],"category_scores_gemma":[0.002695508,0.001233582,0.001645139,0.0003901054,0.001291471,0.001349889,0.000544122,0.003234256,0.001146252],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000652629,"about_ca_system_score_gemma":0.0008464201,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007969896,"about_ca_topic_score_gemma":0.001593402,"domain_scores_codex":[0.99866,0.000788121,0.0000880731,0.0002133856,0.0001085448,0.0001418589],"domain_scores_gemma":[0.9982855,0.0005259181,0.0003376811,0.0002136463,0.0001179392,0.0005192951],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9894918,0.003942683,0.0001952959,0.00009501466,0.0002634033,0.00001354805,0.00001324358,0.00008422216,0.00149693,0.00002104083,0.0001273488,0.004255341],"study_design_scores_gemma":[0.9624395,0.03594415,0.0008474516,0.000006343878,0.0001642348,0.00001199052,0.000005638924,0.0002008557,0.0002058437,0.00003089491,0.000135512,0.00000764958],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919373,0.001915838,0.0007058768,0.0005170098,0.0005204382,0.002350834,0.0008238201,0.0001545181,0.001074504],"genre_scores_gemma":[0.9887204,0.001282648,0.001591797,0.001021213,0.0007223832,0.003111743,0.0010336,0.00003182641,0.002484296],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006033322,"threshold_uncertainty_score":0.0201835,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01394099044181756,"score_gpt":0.2524403988908831,"score_spread":0.2384994084490655,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}